Canada John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation.…
Hungary Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and multinational pharmaceutical companies, the attractiveness of the Hungarian market, and the AIPM’s role in improving the country’s regulatory and reimbursement…
UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…
Czech Republic Jakub Dvořáček, CEO of the Czech Association of Innovative Pharmaceutical Industry (AIFP), describes the thorough review of the reimbursement scheme the association has worked on alongside other key stakeholders in Czech healthcare and evaluates the major change this will bring in terms of access to innovative medicines for patients. Furthermore,…
China PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews, giving an exclusive glimpse into what is currently at the top of the minds of pharma country managers in China.…
GSK In conversation at the FT Global Pharmaceutical and Biotechnology Conference in London,* an energetic Emma Walmsley discussed the strategic and cultural shifts she has implemented in her two and a half years as CEO of iconic British firm GSK, the increasingly important intersection between technology and pharma, and countering the…
UAE Ana Raposo, country director for Gulf Countries at Janssen discusses her role, the main similarities and differences between the various markets throughout the Gulf, mental health, and corporate social responsibility (CSR) initiatives in the region. The Gulf markets are very open to innovation and eager to bring the most…
Czech Republic The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’ While a number of promising steps have already been taken, it is far too soon to tell whether the Czechs…
Hungary Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase funding and shorten approval times. According to the Hungarian Association of Innovative Pharma Manufacturers, since 2016 only 48 new…
Sweden Johan Folkunger, CEO of Philips Sweden, discusses the transformation from a conglomerate into a healthtech company focused on health and wellbeing, the unique partnership with the Karolinska University Hospital including the establishment of a global research hub in Sweden, and the effort to move healthcare away from the hospitals. Folkunger…
Sweden Originally from Croatia, Vatroslav Mateljic was appointed as the general manager of Takeda Sweden in April 2019. Mateljic outlines how Takeda is integrating Shire operations in Sweden, highlights how Sweden’s innovation potential could pave the way for a value-based healthcare system, and how solutions and learnings from the Swedish affiliate…
Sweden Judith Love, country president Sweden and oncology general manager for the Nordics region for Novartis, underlines the need for a new reimbursement system for cell and gene therapies in the region and explains how the Nordics and Sweden can be a pioneer in this field, by initiating early dialogue between…
See our Cookie Privacy Policy Here